China-NINE Cohort：Neuroimmune Network in Elderly / Neurodegeneration

Status

Enrolling by invitation

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07586501

Enrollment

260

Registered

2026-05-14

Start date

2026-01-16

Completion date

2029-01-01

Last updated

2026-05-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cognitive Dysfunction, Cognitive Dysfunction, Cognitive Disorder, Parkinson's Disease (PD)

Keywords

Cognitive impairment, dementia, Alzheimer's disease, biomarker, brain MRI, neuroimaging, cognitive assessment, elderly population, Parkinson's disease

Brief summary

This is an observational study aimed at understanding the cognitive, functional, and behavioral characteristics of Chinese patients with cognitive impairment, exploring the underlying mechanisms, and providing evidence for early diagnosis, treatment, and care of cognitive disorders including dementia. Eligible participants will undergo a series of assessments and examinations, including cognitive and memory scale tests, routine blood tests, ApoE genetic testing, cerebrospinal fluid testing, brain MRI, functional MRI, and FDG-PET/AV45-PET scans when necessary. Additional samples such as saliva, nasal secretions, and stool may also be collected. Most evaluations are provided free of charge to support diagnosis and treatment guidance. Participation is voluntary. All personal information and research data will be kept confidential. Potential benefits include access to expert clinical care and free cognitive assessments for disease evaluation. Possible inconveniences include time commitment and temporary discomfort during examinations; medical support will be provided if needed.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

55 Years to 75 Years

Healthy volunteers

Yes

Inclusion criteria

* Participants with clinically diagnosed cognitive impairment. Patients with clinically diagnosed Parkinson's disease. Healthy control participants.

Exclusion criteria

* Central nervous system infection, head trauma, epilepsy, multiple sclerosis, or other major neurological disorders. Malignant tumors. Family history of genetic disorders.

Design outcomes

Primary

Measure	Time frame	Description
Degree and Type of Cognitive Impairment Assessed by Neuropsychological Scales	From enrollment to the end of treatment at 3 years	Higher scores indicate better cognitive function; lower scores indicate more severe cognitive impairment.

Countries

China

Outcome results